No androgen withdrawal syndrome for enzalutamide: A report of disease dynamics in the postchemotherapy setting

摘要

There is emerging discussion of the value of secondary androgen withdrawal in the postdocetaxel setting by withdrawing abiraterone acetate (AA) [1]. However, to our best knowledge, no evaluation of enzalutamide withdrawal in this setting has been observed or described so far. Enzalutamide is a novel androgen receptor (AR) antagonist currently approved for the treatment of progressive metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy. An alternative therapeutic option in this setting is the androgen biosynthesis inhibitor AA and cabazitaxel [2].